Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Emergence of Co-Infection of Visceral Leishmaniasis in an Iranian Child With Chronic Granulomatous Disease: A Case Report



Abdolsalehi MR1 ; Mohebali M2, 3 ; Keshavarz H2, 3 ; Mahmoudi S4 ; Mamishi S1, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Infectious Diseases, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Center for Research of Endemic Parasites of Iran (CREPI), Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Pediatric Infectious Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Parasitology Published:2021

Abstract

Chronic granulomatous disease (CGD) described as an essential immunodefi-ciency problem of phagocytic cells resulting in a phagocyte dysfunction and ina-bility to kill a spectrum of bacteria and fungi. Despite the fact that CGD patients are more susceptible to intracellular infections, visceral leishmaniasis has been reported rarely in these cases. Here, we report an uncommon case of visceral leishmaniasis in a child with CGD. An 8-yr old boy with CGD presented to the infectious disease ward, Children's Medical Center, Tehran University of Medical Sciences, Iran after the onset of 20 days fever with chronic crusted ulcer approximately 3 cm × 3cm on the left upper limb and a small ulcer measuring 0.5 cm × 0.5 cm on the right knee with moderate secretion. Bone Marrow Aspiration (BMA) and Bone Marrow Biopsies (BMB) of fragmented samples were performed and polymorphic population of hematopoietic cells, Megakaryocytes and Leishman bodies were seen. The patient was treated with meglumine antimoniate (Glucantime®) 20 mg/kg for 28 days and after partial improvement patient dis-charged and continue the treatment at home. Amphotericin B lipid complex (Ambisome®) (3–5 mg/kg per dose once) was administered every 3-4 weeks for 18 months as secondary prophylaxis that was well tolerated and effective. © 2021 Abdolsalehi et al.
Other Related Docs